ALAMEDA, Calif., Jan. 26, 2009 (GLOBE NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company, today confirmed that BVF Acquisition LLC, a wholly owned subsidiary of Biotechnology Value Fund, L.P. (collectively, "BVF"), had commenced an unsolicited tender offer to purchase all of the outstanding shares of Avigen's common stock that BVF does not already own for $1.00 per share in cash.
